Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - 1 hr 32 mins ago
MNK: 97.84 (-0.29), BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)
Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:45PM CST
Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug application for buprenorphine HCl buccal film.
BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15)
3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
PR Newswire Europe - Tue Dec 23, 3:15PM CST
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc , and BioDelivery Sciences International, Inc. announced today that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), ENL.TO: 83.00 (+0.91)
Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)
Endo Announces Appearances at Upcoming Conferences
PR Newswire Europe - Mon Dec 22, 3:01PM CST
Endo International plc announced today that Rajiv De Silva, President and CEO, will present a corporate overview at the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, January 6, 2015 in Boston at 8:00 a.m. Eastern Time and at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 in San Francisco at 2:00 p.m. Pacific Time.
ENDP: 72.10 (+0.34), ENL.TO: 83.00 (+0.91), JPM: 62.48 (unch)
Endo Pharmaceuticals Rises 2.37% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:58PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $70.81 to a high of $73.72. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $72.00 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 72.10 (+0.34)
Why the Earnings Streak Will Continue for Endo International (ENDP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:32AM CST
Endo International plc (ENDP) has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports
ENDP: 72.10 (+0.34)
Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan
PR Newswire - Wed Dec 17, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, December 16, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,068.87, down 0.65% and the NASDAQ Composite closed at 4,547.83, down 1.24%. The S&P 500 finished the session 0.85% lower at 1,972.74. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, whereas the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
AGN: 210.12 (+0.95), ENDP: 72.10 (+0.34), TEVA: 57.09 (+0.33), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11)
CR Bard (BCR) Faces Series of Lawuits - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 4:25PM CST
CR Bard Inc. (BCR) has been hit by a wave of product liability lawsuits over its faulty pelvic mesh products and defective vaginal-mesh implants, which could result in billions of dollars in damages.
BSX: 13.13 (+0.07), JNJ: 104.59 (+0.31), ENDP: 72.10 (+0.34), BCR: 169.10 (-0.44)
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 16, 10:26AM CST
Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, licensing agreements and strong performances.
MDVN: 99.23 (+1.23), OREX: 5.98 (+0.01), ENDP: 72.10 (+0.34), BMRN: 88.18 (+0.89), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15), MNKD: 5.68 (+0.18), CELG: 109.60 (+3.48)
Endo International's SEC form S-4 declared effective
M2 - Fri Dec 12, 7:01AM CST
Healthcare company Endo International (NasdaqGS:ENDP) (TSX:ENL.TO) said on Thursday that its registration statement on Form S-4 has been declared effective by the US Securities and Exchange Commission (SEC) in connection with its acquisition of Auxilium Pharmaceuticals.
ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18)
Auxilium sets special shareholders meeting
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 6:19AM CST
ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18)
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC
PR Newswire Europe - Thu Dec 11, 4:00PM CST
Endo International plc today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the company's Registration Statement on Form S-4. The Form S-4 registers with the SEC Endo's ordinary shares to be issued in connection with the pending acquisition of Auxilium Pharmaceuticals.
ENDP: 72.10 (+0.34), ENL.TO: 83.00 (+0.91), AUXL: 34.40 (+0.18)